<DOC>
	<DOC>NCT02152007</DOC>
	<brief_summary>A study to evaluate safety and efficacy of topical sirolimus to treat plantar keratoderma in adults with PC. Subjects may receive either placebo or treatment with at least 1 foot receiving topical sirolimus at some time. For certain phases of the study treatment assignment to the right and left foot will be randomized in a double blind fashion. Blood levels will test systemic absorption of sirolimus. Other safety and efficacy measures will be taken through the 39-week study duration. Funding Source - FDA OOPD</brief_summary>
	<brief_title>Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)</brief_title>
	<detailed_description />
	<mesh_term>Nails, Malformed</mesh_term>
	<mesh_term>Pachyonychia Congenita</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Subjects must: Be capable of understanding the purpose and risks of the study and sign a written Informed Consent Form (ICF) Be male or female â‰¥ 16 years of age at the time of the screening visit Have a confirmed diagnosis of PC by genotyping (e.g., familial) and clinically correlated painful keratoderma. Have roughly symmetrical calluses of similar severity on the plantar surface of both feet Women of childbearing potential must have a negative serum pregnancy test Subjects, whether male or female, with reproductive potential and who are sexually active must agree to use doublebarrier contraception methods A Subject with any of the following criteria is not eligible for inclusion in this study: Use of other investigational drugs within 30 days of the screening visit and/or has not recovered from any side effects of prior investigational drugs or procedure in the affected area (e.g., a biopsy) Significant condition in the dermatologic treatment area such as trauma, or nonhealing chronic wound Pregnant or nursing (lactating) female, or a positive serum pregnancy test Active infection either systemic or local near the site of treatment requiring chronic or prolonged use of antimicrobial agents Known immunodeficiency including: Hepatitis A; Hepatitis B; Hepatitis C; Human Immunodeficiency Virus (HIV) Prior and Current Treatment Unable to be discontinued from drugs known to either be inducers or inhibitors of CYP3A4/5 enzymes Unable to be discontinued from drugs known to be Pglycoprotein inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pachyonychia congenita</keyword>
</DOC>